Sanofi is a healthcare company engaged in the research, development, manufacturing, and marketing of innovative therapeutic solutions. It covers areas such as diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new G enzyme. Its products includes prescriptions and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines and other medical products. The two young groups Sanofi and Synthélabo merged in May 1999 to create a major new pharmaceutical player. Sanofi dates back to 1973 and Synthélabo to 1970. In December 1999, Rhône-Poulenc and Hoechst Marion Roussel formalized their merger with the creation of the Franco-German group Aventis, one of the world’s largest pharmaceutical companies. In August 2004, Sanofi-Synthelabo acquired Aventis. The takeover was finalized on December 31 of that year, giving birth to sanofi-aventis. On May 6, 2011, sanofi-aventis simplified its name to Sanofi. Sanofi  operates in over 100 countries throughout the world.

Research Grants 255 show all


$91.1M
2016

$135.4M
2017

$55.1M
2018

$18M
2019

$6.5M
2020

Publications 72 show all

  • 8
    Viral Vaccines/immunology
  • 5
    Flavivirus/immunology
  • 5
    Viral Vaccines/adverse effects
  • 5
    West Nile virus/immunology
  • 5
    Yellow Fever Vaccine/immunology
  • 5
    Yellow fever virus/genetics
  • 4
    Yellow Fever Vaccine/therapeutic use
  • 4
    Yellow Fever/prevention & control
  • 4
    Yellow fever virus/immunology
  • 3
    Dengue Virus/genetics

Patents 172,932show all

  • 23,444
    C07D - Heterocyclic compounds
  • 14,742
    C07C - Acyclic or carbocyclic compounds
  • 12,871
    A61K - Preparations for medical, dental, or toilet purposes
  • 6,572
    C09B - Organic dyes or closely-related compounds for producing dyes
  • 5,560
    C07K - Peptides
  • 5,349
    C08F - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
  • 4,774
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 4,727
    A61M - Devices for introducing media into, or onto, the body
  • 4,477
    C08G - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
  • 3,349
    D06P - Dyeing or printing textiles

Clinical Trials 3,479show all

943Phase 3730Phase 2554N/A504Phase 4369Phase 1177Other

Contact Information

54, rue La Boétie
Paris 75008
France

Overview

Total FundingEmployeesLast Funding DateStatus
$310,000,00010000+2014-12-02Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-12-02$310,000,000Private EquityEvotec